# Efficacy, public health impact and optimal use of the Takeda dengue vaccine

Bethan Cracknell Daniels, Neil Ferguson\*, Ilaria Dorigatti\*

MRC Centre for Global Infectious Disease Analysis and the Abdul Latif Jameel Institute for Disease and Emergency Analytics, School of Public Health, Imperial College London, London, UK

\*Corresponding authors

#### Abstract

 $\frac{1}{t}$ Dengue is the most common arboviral infection, causing substantial morbidity and mortality globally.<br>The licensing of Qdenga, a second-generation vaccine developed by Takeda Pharmaceuticals, is The licensing of Queliga, a second-generation vaccine developed by Takeda Thamaceuticals, is<br>therefore timely, but the potential public health impact of vaccination across transmission settings needs<br>to be evaluated. To ad to be evaluated. To address this, we characterised Qdenga's efficacy profile using mathematical models<br>calibrated to published clinical trial data and estimated the public health impact of routine vaccine use.<br>We find that to a dibrated to published clinical trial data and estimated the public health impact of routine vaccine use.<br>We find that efficacy depends on the infecting serotype, serological status, and age. We estimate that<br>vaccinati We find that efficacy depends on the infecting serotype, serological status, and age. We estimate that<br>vaccination of children aged over six years in moderate to high dengue transmission settings<br>(seroprevalence at 9 years vaccination of children aged over six years in moderate to high dengue transmission settings<br>(seroprevalence at 9 years of age > 60%) could reduce the burden of hospitalised dengue by 10-22% on<br>average over ten years. We (seroprevalence at 9 years of age > 60%) could reduce the burden of hospitalised dengue by 10-22% on average over ten years. We find some evidence of a risk of vaccine-induced disease enhancement in seronegative vaccine r (serverage over ten years. We find some evidence of a risk of vaccine-induced disease enhancement in<br>seronegative vaccine recipients for dengue serotypes 3 and 4, especially for children under six years of<br>age. Because of seronegative vaccine recipients for dengue serotypes 3 and 4, especially for children under six years of<br>age. Because of this, the benefits of vaccination in lower transmission settings are more uncertain, and<br>more data on

#### **Introduction**

serving and dentistive variable vaccination in lower transmission settings are more uncertain, and<br>age. Because of this, the benefits of vaccination in lower transmission settings are more uncertain, and<br>more data on the l age. Because of this, the benefits of Qdenga against serotypes 3 and 4 are needed.<br>
Introduction<br>
With more than half of the world's population currently at risk of dengue infection, novel control<br>
methods, including vacci more data on the long-term efficacy of Adenga against serotypes 3 and 4 are needed.<br>With more than half of the world's population currently at risk of dengue inferent<br>methods, including vaccines, are urgently needed to red methods, including vaccines, are urgently needed to reduce disease burden and resulting economic<br>impacts. Historically, developing safe and effective dengue vaccines has been challenging due to the<br>presence of four antige impacts. Historically, developing safe and effective dengue vaccines has been challenging due to the<br>presence of four antigenically distinct dengue serotypes (DENV1-4) that elicit cross-reactive immunity and<br>can enhance t presence of four antigenically distinct dengue serotypes (DENV1-4) that elicit cross-reactive immunity and<br>can enhance the severity of secondary infections through antibody-dependent enhancement<sup>1</sup>. The first<br>licensed den can enhance the severity of secondary infections through antibody-dependent enhancement<sup>1</sup>. The first<br>licensed dengue vaccine, Dengvaxia, developed by Sanofi Pasteur, was belatedly found to increase the risk<br>of hospitalis can enhance the severity of secondary infections through antibody-dependent enhancement". The first<br>licensed dengue vaccine, Dengvaxia, developed by Sanofi Pasteur, was belatedly found to increase the risk<br>of hospitalisat Interval (CI): 1.14 to 2.70)<sup>2</sup>, confirming earlier modelling of the phase III trial of that vaccine which had highlighted this potential risk<sup>3</sup>. Consequently, Dengvaxia is now only indicated for use in individuals with p interval (CI): 1.14 to 2.70)<sup>2</sup>, confirming earlier modelling of the phase III trial of that vaccine which had<br>highlighted this potential risk<sup>3</sup>. Consequently, Dengvaxia is now only indicated for use in individuals with<br> interval (CI): 1.14 to 2.70)<sup>2</sup><br>highlighted this potential r<br>prior dengue exposure (se<br>dengue to date, is in limit<br>dengue vaccine that can be<br>Previous work has shown highlighted this potential risk<sup>3</sup>. Consequently, Dengvaxia is now only indicated for use in individuals with highlighted this potential risk<sup>3</sup>. Consequently, Dengvaxia is now only indicated for use in individuals with<br>prior dengue exposure (seropositives), and due to the absence of an accurate rapid antibody test for<br>dengue to d

dengue to date, is in limited use. There therefore remains an unmet need for a safe and efficacious<br>dengue vaccine that can be used programmatically without pre-vaccination testing.<br>Previous work has shown that high neutr dengue vaccine that can be used programmatically without pre-vaccination testing.<br>Previous work has shown that high neutralising antibody titres against dengue are associated with<br>protection, and low-to-moderate antibody Previous work has shown that high neutralising antibody titres against dengue<br>protection, and low-to-moderate antibody titres are associated with an increased<br>and hospitalisation  $4-6$ . However, an exact titre for protect トーミ くりく protection, and low-to-moderate antibody titres are associated with an increased risk of severe disease<br>and hospitalisation  $4-6$ . However, an exact titre for protection has not yet been identified, and it is<br>expected tha and hospitalisation  $^{4-6}$ . However, an exact titre for protection has not yet been identified, and it is expected that this will depend on the assay used, the infecting serotype (and potentially genotype), and most like and hospitalisation  $4^{\circ}$ . However, an exact titre for protection has not yet been identified, and it is expected that this will depend on the assay used, the infecting serotype (and potentially genotype), and most like most likely an individual's prior exposure to other serotypes and related flaviviruses<sup>7,8</sup>. Nevertheless, vaccine-induced antibody titres correlate with protection at the population level<sup>9</sup> and are good predictors antibody titres as immunogenicity metric for second-generation dengue vaccines<sup>11</sup>. of disease risk<sup>10</sup>, leading to the World Health Organisation (WHO) recommending the use of neutralising of disease risk<sup>20</sup>, leading to the World Health Organisation (WHO) recommending the use of neutralising<br>antibody titres as immunogenicity metric for second-generation dengue vaccines<sup>11</sup>.<br>TE: This preprint reports new re

7

for use in several countries, including Brazil where vaccine rollout began in early 2024<sup>12</sup>. Qdenga is a tetravalent chimeric live-attenuated vaccine using DENV2 as the backbone for all four serotype components, but subs for use in several countries, including Brazil where vaccine rollout began in early 2024<sup>44</sup>. Qdenga is a<br>tetravalent chimeric live-attenuated vaccine using DENV2 as the backbone for all four serotype<br>components, but subst components, but substituting DENV1, 2 and 4 pre-membrane and envelope proteins for those<br>serotypes<sup>13</sup>. Qdenga's efficacy was evaluated in a multi-country phase III trial across Asia and South<br>America that enrolled approx serotypes<sup>13</sup>. Qdenga's efficacy was evaluated in a multi-country phase III trial across Asia and South America that enrolled approximately 21,000 participants aged 4-16 years, who were randomised 2:1 to receive two doses serotypes<sup>25</sup>. Qdenga's efficacy was evaluated in a multi-country phase III trial across Asia and South<br>America that enrolled approximately 21,000 participants aged 4-16 years, who were randomised 2:1 to<br>receive two doses From 1-57 months post-first dose, the average VE in the safety population (individuals who received at<br>least one dose of the vaccine or placebo, 90 days apart<sup>14</sup>. Building on the experience with Dengvaxia,<br>and disease ou receive two doses of Qdenga or placebo, 90 days apart<sup>24</sup>. Building on the experience with Dengvaxia, vaccine efficacy (VE) was evaluated by baseline serostatus prior to vaccination, infecting serotype, age, and disease o and disease outcome (defined as symptomatic dengue and hospitalisation) for all trial participants, at 12<br><sup>14</sup>, 18<sup>.15</sup>, 24<sup>.16</sup>, 36<sup>.17</sup>, and 54 months<sup>18</sup> post-second dose.<br>From 1-57 months post-first dose, the average

<sup>14</sup>, 18<sup>-15</sup>, 24<sup>-16</sup>, 36<sup>-17</sup>, and 54 months<sup>-18</sup> post-second dose.<br>
From 1-57 months post-first dose, the average VE in the safety population (individuals who received at least one dose of the vaccine or placebo) was e symptomatic virologically confirmed dengue (VCD) and 84.1% (95% CI: 77.8 to 88.6) against hospitalised<br>VCD over all serotypes and baseline serostatuses<sup>18</sup>. However, VE waned over time, from an average of<br>80.2% (95% CI: 73 From 1-67 months post-first dose of the vaccine or placebo) was estimated at 61.2% (95% Cl: 56.0 to 65.8) against<br>symptomatic virologically confirmed dengue (VCD) and 84.1% (95% Cl: 77.8 to 88.6) against hospitalised<br>VCD symptomatic virologically confirmed dengue (VCD) and 84.1% (95% CI: 77.8 to 88.6) against hospitalised<br>VCD over all serotypes and baseline serostatuses<sup>18</sup>. However, VE waned over time, from an average of<br>80.2% (95% CI: 7 Symptomate intergrang continuous analysis. However, VE wanted over time, from an average of 80.2% (95% CI: 73.3 to 85.3) against symptomatic VCD in the per-protocol population (individuals without any major protocol viola VCD over all serotypes and baseline serostatuses<sup>20</sup>. However, VE waned over time, from an average of 80.2% (95% Cl: 73.3 to 85.3) against symptomatic VCD in the per-protocol population (individuals without any major prot any major protocol violations, including not receiving both doses of the correct assignment of Qdenga or placebo) in year 1 to 44.7% (95% CI: 32.5 to 54.7) in year 3. VE also varied by serotype and baseline serostatus, wi placebo) in year 1 to 44.7% (95% Cl: 32.5 to 54.7) in year 3. VE also varied by serotype and baseline<br>serostatus, with higher VE in seropositive individuals and against DENV2<sup>17</sup>. Consistent with the VE<br>estimates, neutral serostatus, with higher VE in seropositive individuals and against  $DENV2^{17}$ . Consistent with the VE<br>estimates, neutralising antibody titres induced by Qdenga were highest and more durable in seropositive<br>individuals and serostatus, with higher VE in seropositive individuals and against DENV2<sup>-7</sup>. Consistent with the VE<br>estimates, neutralising antibody titres induced by Qdenga were highest and more durable in seropositive<br>individuals and a

individuals and against DENV2<sup>18</sup> with specific antibody<sup>19</sup> and T cell<sup>20,21</sup> responses most strongly elicited against the DENV2 backbone virus.<br>In baseline seronegative individuals, the phase III trial showed no statist In baseline seronegative individua<br>protection against DENV3 and DEI<br>15.5% (95% CI: -108.2 to 35.9) and<br>point estimates of VE against hosp<br>recipients (VE: -87.9%, 95% CI: -5<br>seronegative vaccinees occurred in protection against DENV3 and DENV4, with average VE estimates up to 57 months post-first dose of 15.5% (95% CI: -108.2 to 35.9) and -105.6% (95% CI: -628.7 to 42.0), respectively<sup>18</sup>. During this period, point estimates o 15.5% (95% CI: -108.2 to 35.9) and -105.6% (95% CI: -628.7 to 42.0), respectively<sup>18</sup>. During this period, point estimates of VE against hospitalisation following a DENV3 infection were negative in seronegative recipients precipients (VE: -87.9%, 95% CI: -573.4 to 47.6), although 6 out of the 11 DENV3 hospitalisations in<br>seronegative vaccinees occurred in Sri Lanka, where hospitalisation tends to be more frequent than in<br>other countries<sup>18</sup> recipients (VE: 1992), 2000 and Sri Lanka, where hospitalisation tends to be more frequent than in other countries<sup>18</sup>. Additionally, there were two cases of severe dengue in the seronegative vaccine group, both DENV3, and served in the seronegative vaccine strategy of the countries<sup>18</sup>. Additionally, there were two cases of severe dengue in the seronegative vaccine group, both DENV3, and none in the placebo group<sup>22</sup>. Using the WHO 1997 cri other countries<sup>20</sup>. Additionally, there were two cases of severe dengue in the seronegative vaccine group, both DENV3, and none in the placebo group<sup>22</sup>. Using the WHO 1997 criteria for dengue haemorrhagic fever, there we both DENV3, and none in the placebo group<sup>22</sup>. Using the WHO 1997 criteria for dengue haemorrhagic<br>fever, there were two cases in the seronegative placebo group (DENV1 and DENV3) and four in the<br>vaccine group (all DENV3). Fever, there are two cases in the series in the series in the series in the series of a risk of vaccine-associated disease enhancement in seronegative recipients for DENV3 and DENV4, despite the lack of statistical signifi

vacak signal of a risk of vaccine-associated disease enhancement in seronegative recipients for DENV3 and<br>DENV4, despite the lack of statistical significance.<br>While the published VE estimates for Qdenga provide estimates o While the published VE estimates for Qdenga provide estimates of how VE vary by serotype, age,<br>While the published VE estimates for Qdenga provide estimates of how VE vary by serotype, age,<br>serostatus and over time, most s While the published VE estimates for Qdenga<br>serostatus and over time, most such estimates<br>variables. For instance, no efficacy estimates have<br>support optimal deployment, it is also importance.<br>vaccination and evaluate its ハミ ハミー serostatus and over time, most such estimates are only available stratified by at most two of those<br>variables. For instance, no efficacy estimates have been published by both serotype and age to date. To<br>support optimal de variables. For instance, no efficacy estimates have been published by both serotype and age to date. To<br>support optimal deployment, it is also important to estimate the public health impact of Qdenga<br>vaccination and evalua support optimal deployment, it is also important to estimate the public health impact of Qdenga<br>vaccination and evaluate its suitability across different transmission settings. Here we address these<br>knowledge gaps. We firs is vaccination and evaluate its suitability across different transmission settings. Here we address these<br>knowledge gaps. We first develop a survival model calibrated to published phase III data to infer how<br>antibody titr vaculate and the latest WHO position paper on dengue vaccination<sup>22</sup>.<br>
Showledge gaps. We first develop a survival model calibrated to published phase III data to infer how<br>
antibody titre dynamics can be translated into antibody titre dynamics can be translated into estimates of protection. Second, we embed this VE model<br>into a previously published dengue transmission model<sup>3</sup> to simulate the potential public health impact of<br>programmati into a previously published dengue transmission model<sup>3</sup> to simulate the potential public health impact of programmatic use of Qdenga, estimating impacts at both the population- and individual-level. This work informed th programmatic use of Qdentific Advisory Board of Experts (SAGE) recommendations on dengue vaccines<sup>23</sup><br>and the latest WHO position paper on dengue vaccination<sup>22</sup>.<br>2 informed the WHO Scientific Advisory Board of Experts (SAGE) recommendations on dengue vaccines<sup>23</sup><br>and the latest WHO position paper on dengue vaccination<sup>22</sup>.<br>2 and the latest WHO position paper on dengue vaccination<sup>44</sup>.<br>And the latest WHO position<br>apper on dengue vaccination<sup>44</sup>.<br>And the latest WHO position paper on dengue vaccination<sup>44</sup>.

#### **Results**

#### Vaccine efficacy against symptomatic disease and hospitalisation

symptomatic and hospitalised cases (Supplementary Figures 1a and 2). The model extends the correlates<br>of protection model first proposed by Khoury *et al.<sup>24</sup>* for SARS-CoV-2, allowing us to link the neutralising<br>antibody symptomatic and hospitalised cases (Supplementary Figures 1a and 2). The model extends the correlates<br>of protection model first proposed by Khoury *et al.*<sup>24</sup> for SARS-CoV-2, allowing us to link the neutralising<br>antibody of protection model first proposed by Khoury *et al.*<sup>24</sup> for SARS-CoV-2, allowing us to link the neutralising<br>antibody titres induced by Qdenga (**Supplementary Figure 3**) to the risk of disease in the vaccine arm<br>compared antibody titres induced by Queriga (Supplementary Figure 3) to the risk of disease in the vaccine arm<br>compared to the placebo group. Of the 31 model variants explored (Supplementary Figure 4), the optimal<br>model following m compared to the placebo group. Of the 31 model variants explored (Supplementary Figure 4), the optimal<br>model following model selection reproduced the symptomatic case and hospitalisation attack rates<br>observed over the 54 m model for the 54 months post-second dose by inferring the relative serotype-, serostatus-, outcome-<br>and age-specific titres required for protection and testing the hypothesis of potential vaccine-associated<br>enhancement in and age-specific titres requires individuals. We fit the model to the reported number of cases stratified by<br>trial arm, age group, serotype, and baseline serostatus at the finest granularity allowed by the published<br>data ( trial arm, age group, serotype, and baseline serostatus at the finest granularity allowed by the published<br>data (Figure 1a-c, Supplementary Figures 5-7). Posterior parameter estimates are given in<br>Supplementary Table 1.<br>We

We estimate high VE against symptomatic and hospitalised DENV2 in both seronegative and seropositive data (Figure 1a-c, Supplementary Figures 5-7). Posterior parameter estimates are given in<br>Supplementary Table 1.<br>We estimate high VE against symptomatic and hospitalised DENV2 in both seronegative and seropositive<br>individu Supplementary Table 1.<br>Supplementary Table 1.<br>We estimate high VE against symptomatic and hospitalised DENV2 in both seronegative and seropositive<br>individuals, regardless of age (Figure 1d and Supplementary Figure 8). In s Supplementary Table 1.<br>We estimate high VE againdividuals, regardless constimate more moderal<br>serotypes. Conversely, for<br>enhanced risk of sympinfection starting from 3 \<br>i ( \_s ( i \_i individuals, regardless of age (Figure 1d and Supplementary Figure 8). In seropositive individuals, we<br>estimate more moderate protection against symptomatic disease and hospitalisation for the other<br>serotypes. Conversely, individuals, regardless of age (Figure 1d and Supplementary Figure 8). In seropositive marviduals, we<br>estimate more moderate protection against symptomatic disease and hospitalisation for the other<br>serotypes. Conversely, f serotypes. Conversely, for seronegative vaccinated subjects in the 4-5 years age group, we estimate an enhanced risk of symptomatic disease (negative average VE) following DENV1, DENV3, and DENV4 infection, starting from 3 enhanced risk of symptomatic disease (negative average VE) following DENV1, DENV3, and DENV4<br>infection, starting from 3-12 months post second dose, albeit credible intervals always include zero. For<br>DENV3 and DENV4 we also infection, starting from 3-12 months post second dose, albeit credible intervals always include zero. For<br>DENV3 and DENV4 we also estimate an enhanced risk of hospitalisation from 9- and 26-months post<br>second dose in the s DENV3 and DENV4 we also estimate an enhanced risk of hospitalisation from 9- and 26-months post<br>second dose in the seronegative 4–5-year age group, respectively. For seronegative children over 6 years<br>old, we estimate a po second dose in the seronegative 4–5-year age group, respectively. For seronegative children over 6 years<br>old, we estimate a positive average VE against both symptomatic disease and hospitalisation for DENV1<br>for the entire second dose in the set imate a positive average VE against both symptomatic disease and hospitalisation for DENV1 for the entire follow up period (54 months post second dose) but negative average VEs were estimated for DEN for the entire follow up period (54 months post second dose) but negative average VEs were estimated<br>for DENV3 and DENV4 from approximately 3 years post second dose. The large uncertainties around the<br>VE estimates against for DENV3 and DENV4 from approximately 3 years post second dose. The large uncertainties around the<br>VE estimates against hospitalisation and for DENV3 and DENV4 are due to the small case numbers<br>observed during the trial. VE estimates against hospitalisation and for DENV3 and DENV4 are due to the small case numbers<br>observed during the trial. The VE estimates projected up to 15 years post-vaccination as a function of<br>time and neutralising an

VE ESTIMITED SURVEY AND THE VERTIFY AND THE VIDEO STRESS AGAINST THE VIDEO INTERNATION AS A function of<br>The and neutralising antibody titre are shown in **Supplementary Figures 9 and 10**.<br>Our model explicitly included a par The and neutralising antibody titre are shown in **Supplementary Figures 9 and 10**.<br>Our model explicitly included a parameter determining the maximum potential level of vaccine-associated<br>disease enhancement, which was esti time and neutralising antibody titre are shown in Supplementary Figures 9 and 10.<br>Our model explicitly included a parameter determining the maximum potential leve<br>disease enhancement, which was estimated to be 84% (95% Crl ( ( ( ( )<br>( ) ) ) disease enhancement, which was estimated to be 84% (95% Crl: 13% to 184%). The Bayes factor<br>comparing our model with and without disease enhancement indicates evidence for enhancement<br>(Supplementary Figure 11) regardless o comparing our model with and without disease enhancement indicates evidence for enhancement<br>(Supplementary Figure 11) regardless of the prior distribution used, even though the magnitude of the<br>estimated enhancement parame (Supplementary Figure 11) regardless of the prior distribution used, even though the magnitude of the estimated enhancement parameter was influenced by the choice of the prior distribution. The results of sensitivity analy (Supplementary Figure 11) regardless of the prior distribution dised, even though the magnitude of the<br>estimated enhancement parameter was influenced by the choice of the prior distribution. The results of<br>sensitivity anal sensitivity analysis on the period of cross-protective immunity between serotypes and whether there is<br>clinical disease in post-secondary infections are shown in **Supplementary Figure 12**. When fitting to<br>simulated data, a

#### Population impact of routine Qdenga vaccination

sensitivity analysis on the period of cross-process-protein in Supplementary Figure 12. When fitting to simulated data, all parameters were recovered well (Supplementary Figure 13).<br>Population impact of routine Qdenga vacc clinical disease in post-secondary infections are shown in Supplementary Figure 12. When mang-to-<br>simulated data, all parameters were recovered well (Supplementary Figure 13).<br>To estimate the impact of routine Qdenga vacci Simulated data, all parameters were recovered well (Supplementary Figure 13).<br>
Population impact of routine Qdenga vaccination<br>
To estimate the impact of Qdenga vaccination, we integrated our fitted VE m<br>
multi-strain stoc |
|
|
| To estimate the impact of Qdenga vaccination, we integrated our fitted VE model (Figure 1d) mio the<br>multi-strain stochastic compartmental model of dengue transmission previously used to investigate the<br>potential impact of potential impact of Dengvaxia<sup>3</sup>. We explored four different hypotheses of the vaccine's mode of action, combining two assumptions regarding protection (against disease only, VS, or also against infection, VI [Figure 1D]), potential impact of Dengvaxia<sup>3</sup>. We explored four different hypotheses of the vaccine's mode of action, combining two assumptions regarding protection (against disease only, VS, or also against infection, VI [Figure 1D]), (Figure 1D]), with two assumptions about the duration of VE decay (up to 5 years, D5, or 15 years, D15)<br>(Supplementary Figures 9). Given the limited data available<sup>25</sup>, we assumed that protection against<br>infection require (Supplementary Figures 9). Given the limited data available<sup>25</sup>, we assumed that protection against infection requires a higher titre compared to protection against symptomatic disease and that vaccine-<br>associated enhance (Supplementary Figures 9). Given the limited data available<sup>25</sup>, we assumed that protection against<br>infection requires a higher titre compared to protection against symptomatic disease and that vaccine-<br>associated enhance associated enhancement applies only to clinical outcomes5 (See SI Section 3.3 and Supplementary Figure

14). We examine a range of transmission settings with american torces of infection (characterised by the average seropositivity of 9-year-olds, in line with our previous work<sup>3</sup>). For each transmission intensity level, vac average seropositivity of 9-year-olds, in line with our previous work<sup>3</sup><br>level, vaccine mode of action, coverage level (20%, 40%, 60%, 80%), ag<br>population demography (Brazil and the Philippines), we sampled 200 p<br>our VE mo average seropositivity of 9-year-olds, in line with our previous work<sup>3</sup>). For each transmission intensity<br>level, vaccine mode of action, coverage level (20%, 40%, 60%, 80%), age of vaccination (4-12 years), and<br>population population demography (Brazil and the Philippines), we sampled 200 posterior parameter estimates from<br>our VE model (Figure 1d) and for each such posterior sample we ran 50 simulations of the dengue<br>transmission model, givi

population demography (Brazil and Torrom-Pennsylver and position of the dengue<br>transmission model, giving 10,000 simulations in total per scenario (Supplementary Figure 1b).<br>Figure 2a shows the population impact, summarise our VE model (righte 1d) and for each such position sample we ran 50 simulations of the dengue<br>transmission model, giving 10,000 simulations in total per scenario (Supplementary Figure 1b).<br>Figure 2a shows the population i Figure 2a shows the population impact, summarised as the total proportion of cases averte<br>years, assuming the Brazilian demography, 80% vaccination coverage in 6-year-olds, and that<br>for 15 years (scenarios VS\_D15 and VI\_D1 | \<br>| f<br>| i Figure 2a shows the population impact, summarised as the total proportion of cases averted over 10<br>years, assuming the Brazilian demography, 80% vaccination coverage in 6-year-olds, and that VE wanes<br>for 15 years (scenario years, assuming the articles VS\_D15 and VI\_D15). Supplementary Figures 15-17 show that the expected<br>impacts assuming the Philippines demography and that antibody waning lasts for 5 years, are similar to<br>the scenario presen for 15 years (seenarios VS\_D15 and VI\_D15). Supplementary Figures 15-17 show that the expected<br>impacts assuming the Philippines demography and that antibody waning lasts for 5 years, are similar to<br>the scenario presented i impacts are impact in the main analysis (Figure 2a). Under the VS assumption, we find that the population-level impact increases as the intensity of transmission increases whilst under the VI assumption the population-leve the scenario presented in the main analysis (rigure 2a). Onder the VS assumption, we find that the<br>population-level impact increases as the intensity of transmission settings with <50% seropositive<br>9-year-olds on average ( population-level impact is similar across all transmission settings with <50% seropositive<br>9-year-olds on average (Figure 2a). Regardless of the transmission setting or VE against infection, the<br>population impact is modest 9-year-olds on average (Figure 2a). Regardless of the transmission setting or VE against infection, the population impact is modest, with the mean proportion of symptomatic cases prevented over 10 years ranging from 1.6% t 9 year-olds on average (Figure 2a). Regardless of the transmission setting or VE against infection, the<br>population impact is modest, with the mean proportion of symptomatic cases prevented over 10 years<br>ranging from 1.6% t population 1.6% to 13.7% under the VS scenario and from 8.9% to 17.2% under the VI scenario,<br>depending on transmission intensity. The mean proportion of hospitalisations averted is slightly higher,<br>rising to 22.4% (95% Crl

ranging from 1.6% to 12.6% to 13.3%) assuming the VI scenario in the highest transmission settings.<br>Tising to 22.4% (95% CrI: 17.8% to 28.3%) assuming the VI scenario in the highest transmission settings.<br>Figure 2b shows t rising to 22.4% (95% Crl: 17.8% to 28.3%) assuming the VI scenario in the highest transmission settings.<br> **Figure 2b** shows the population impact by serotype, which highlights the potential for small negative<br>
impacts agai Figure 2b shows the population impact by serotype, which highlights the potential for small negati<br>impacts against DENV1, DENV3, and DENV4 in low-to-moderate transmission settings. In other words,<br>low-to-moderate transmiss |
|
|
| Figure 2b shows the population impact by serotype, which highlights the potential for small negative<br>impacts against DENV1, DENV3, and DENV4 in low-to-moderate transmission settings. In other words, in<br>low-to-moderate tran impacts against DENV1, DENV3, and DENV4 in low-to-moderate transmission settings. In other words, in<br>low-to-moderate transmission settings, most of the positive impact of vaccination observed at the<br>population level in bot

population level in both the VI and VS scenarios can be attributed to the prevention of DENV2 cases<br>(Figure 2b).<br>Figure 3 and Supplementary Figure 18 present the population impact by age of vaccination in the<br>Philippines a population level in both the VS assumption (Figure 3)<br>Figure 3 and Supplementary Figure 18 present the population impact by age of vaccination in the<br>Philippines and Brazil, respectively. In low to moderate transmission se (Figure 2b).<br>Figure 3 an<br>Philippines<br>insensitive t<br>seropositivit<br>reductions i III<br>Iit<br>It Figure 3 and Supplementary Figure 18 present the population impact by age of vacemation in the<br>Philippines and Brazil, respectively. In low to moderate transmission settings the impact is relatively<br>insensitive to the age Philippines and Brazil, respectively. Interactive transmission (Figure 3). In moderate to high<br>transmission settings, the optimal age of vaccination decreases from age 11 to 6 as average 9-year-old<br>seropositivity increases Insensitive to the age of vaccination, especially ander the VS assumption (Figure 3). In moderate to high<br>transmission settings, the optimal age of vaccination decreases from age 11 to 6 as average 9-year-old<br>seropositivit transmission settings, the optimal age of vacuum of the VS assumption (Figure 3). Under the VS assumption,<br>reductions in the coverage from 80% to 20% reduce impact proportionately (i.e., by 75%) regardless of<br>the transmiss seropositivity increases from 50% to 90%, under the VS assumption (Figure 3). Onder the VS assumption, reductions in the coverage from 80% to 20% reduce impact by between 68% to 74%, depending on the transmission intensity the transmission setting, whereas under the VI assumption, reducing coverage from 80% to 20% reduces<br>the impact by between 68% to 74%, depending on the transmission intensity (**Supplementary Figure 19-**<br>20).<br>Individual-lev

#### Individual-level impact of routine Qdenga vaccination

the impact by between 68% to 74%, depending on the transmission intensity (Supplementary Figure 19-<br>20).<br>Individual-level impact of routine Qdenga vaccination<br>Whilst the overall average population impact is always positive 20).<br>20).<br>Individual-level impact of routine Qdenga vaccination<br>Whilst the overall average population impact is always positive, the individual benefits and risks of<br>vaccination – measured as the proportion of cases avert 20).<br>Indi<br>Whil<br>vacc<br>shov<br>posi vaccination – measured as the proportion of cases averted in the first vaccinated cohort over ten years –<br>show a more complex picture (Figure 4 and Supplementary Figures 21-23). The mean individual impact is<br>positive, with show a more complex picture (**Figure 4** and **Supplementary Figures 21-23**). The mean individual impact is<br>positive, with 20-47% and 42-68% of symptomatic cases and hospitalisations averted in vaccinated<br>individuals over 1 show a more complex picture (Figure 4 and Supplementary Figures 21-23). The mean individual mipact is<br>positive, with 20-47% and 42-68% of symptomatic cases and hospitalisations averted in vaccinated<br>individuals over 10 yea individuals over 10 years, respectively. Seropositive individuals always benefit from vaccination, with 40-55% and 63-75% of symptomatic and hospitalised cases averted, respectively. Conversely, whilst the mean impact is p 55% and 63-75% of symptomatic and hospitalised cases averted, respectively. Conversely, whilst the mean<br>impact is positive for seronegative vaccinees, negative impacts in low-to-moderate transmission settings<br>are possible impact is positive for seronegative vaccinees, negative impacts in low-to-moderate transmission settings<br>are possible, as demonstrated by the negative lower bound of the 95% uncertainty intervals (Figure 4)<br>reflecting bot impact is possible, as demonstrated by the negative lower bound of the 95% uncertainty intervals (Figure 4) reflecting both the uncertainty in the VE estimates (Figure 1d) and in the circulating serotypes across the simula are possible, as demonstrated by the negative lower bound of the 95% uncertainty intervals (rigure 4)<br>reflecting both the uncertainty in the VE estimates (Figure 1d) and in the circulating serotypes across the<br>simulations. reflecting both the uncertainty in the VE estimates (Figure 1d) and in the circulating serotypes across the<br>simulations.

Figure 5a shows that overall, vacehiation is expected to avert 95 (95% Cri. 25 to 178) cases and 14 (95% CrI: 1-23) hospitalisations (assuming 9% of symptomatic cases are hospitalised) per 1,000 vaccinated individuals in m individuals in moderate transmission settings (at least 60% seropositive 9-year-olds on average),<br>estimates which are driven primarily by the prevention of cases in seropositive individuals. In<br>seronegative individuals, sy estimates which are driven primarily by the prevention of cases in seropositive individuals. In<br>seronegative individuals, symptomatic cases are averted almost entirely against DENV2 (Figure 5b),<br>regardless of the transmis seronegative individuals, symptomatic cases are averted almost entirely against DENV2 (Figure 5b), regardless of the transmission setting. Notably, negative DENV3 impacts are more likely than positive in seronegative indiv

#### Population screening

serological screening, as recommended for Dengvaxia<sup>11</sup>. Assuming a diagnostic test with 94.7% specificity regardless of the transmission settings with  $<60\%$  seropositive 9-year-olds on average.<br>
Population screening<br>
A potential strategy to mitigate the risk in seronegative recipients (Figure 4) is through pre-vaccination<br> Population screening<br>A potential strategy to mitigate the risk in seronegative recipients (Figure 4) is through pre-va<br>serological screening, as recommended for Dengvaxia<sup>11</sup>. Assuming a diagnostic test with 94.7% s<br>and 8 Expecting strategy to mitigate the risk in seronegative recipients (rigure 4) is through pre-vaccination<br>serological screening, as recommended for Dengvaxia<sup>11</sup>. Assuming a diagnostic test with 94.7% specificity<br>and 89.6% serological screening, as recommended for Dengvaxia<sup>24</sup>. Assuming a diagnostic test with 94.7% specificity<br>and 89.6% sensitivity<sup>26</sup>, and either the VI or VS mode of vaccine action, we find that pre-vaccination<br>screening r and 89.6% sensitivity<sup>26</sup>, and either the VI or VS mode of vaccine action, we find that pre-vaccination screening reduces the population impact of vaccination on symptomatic disease and hospitalisations by 29-33% in the h screening reduces the population impact of vaccination on symptomatic disease and hospitalisations by<br>29-33% in the highest transmission setting and 82-85% in the lowest transmission setting (Supplementary<br>Figure 24-25). A 29-33% in the highest transmission setting and 82-83% in the lowest transmission setting (Supplementary<br>Figure 24-25). As a result, the proportions of symptomatic and hospitalised cases averted over 10 years<br>are <15% acros Figure 24-25). As a result, the proportions of symptomate and hospitalised cases averted over 10 years<br>are <15% across all transmission settings when implementing pre-vaccination screening. This is driven by<br>the loss of pr the loss of protection against DENV1 and DENV2 in seronegative recipients (Figure 5b). The impact of pre-<br>vaccination screening on vaccinated individuals is shown in **Supplementary Figures 26-27.** Overall,<br>screening increa the loss of protection against DENV1 and DENV2 in seronegative recipients (Figure 5b). The impact of pre-<br>vaccination screening increases the individual impact, as a higher proportion of the vaccinated individuals are<br>sero vaccination screening on vaccinated individuals is shown in Supplementary Figures 26-27. Overall,<br>screening increases the individual impact, as a higher proportion of the vaccinated individuals are<br>seropositive. In the ser

#### Impact of vaccination on serotype dynamics

seropositive. In the seronegative individuals who are vaccinated due to imperfect test specificity,<br>screening does not change the proportion of cases averted.<br>Impact of vaccination on serotype dynamics<br>Given the imbalanced screening does not change the proportion of cases averted.<br>Impact of vaccination on serotype dynamics<br>Given the imbalanced serotype-specific efficacy profile (Figure 1d) and population impacts (Figure 2b), we<br>investigated screening and the proportion of change the proportion of changes are proportional impact Given the imbalanced serotype-specific efficacy profile (Figure investigated the extent to which vaccination assuming transmission) c ן<br>it<br>if Given the imbalanced serotype-specific efficacy profile (Figure 1d) and population impacts (Figure 2b), we investigated the extent to which vaccination assuming the VI scenario (where vaccination affects transmission) coul transmission) could impact serotype-specific dengue dynamics. Specifically, we tested whether the<br>introduction of the Qdenga vaccine could (i) eliminate DENV2 in settings with low DENV2 circulation and<br>favour the circulati introduction of the Qdenga vaccine could (i) eliminate DENV2 in settings with low DENV2 circulation and<br>favour the circulation of the other serotypes and (ii) increase the dominance of DENV3 in settings with<br>high DENV3 cir favour the circulation of the other serotypes and (ii) increase the dominance of DENV3 in settings with high DENV3 circulation. We investigated changes in the serotype-specific dynamics among the 1,000 simulations that, in high DENV3 circulation. We investigated changes in the serotype-specific dynamics among the 1,000<br>simulations that, in the absence of vaccination, had the lowest and highest DENV2 and DENV3 incidences,<br>respectively. Figure high DENV3 incidences, include that, in the absence of vaccination, had the lowest and highest DENV2 and DENV3 incidences, respectively. Figures 6a-b show example transmission dynamics with and without vaccination and demo simulations that, in the absolute of vacanties, in the absence of vacanties, in the absence of vaccination and<br>demonstrate how, under the VI assumption, outbreak peaks are expected to change in both timing and<br>magnitude, e

respectively. Figures 6a-b show example transmission dynamics with and without vacemation and<br>demonstrate how, under the VI assumption, outbreak peaks are expected to change in both timing and<br>magnitude, especially in sett magnitude, especially in settings with higher transmission intensities.<br>In settings with low-to-moderate transmission intensity with limited DENV2 circulation, we expect<br>vaccination to reduce slightly DENV2 dominance, with In settings with low-to-moderate transmission intensity with limit<br>vaccination to reduce slightly DENV2 dominance, with a lesser imp<br>(Figure 6c-e). Conversely, we estimate that in low transmission setting<br>introduction of Q | \<br>| ( |
| | In section to reduce slightly DENV2 dominance, with a lesser impact in higher transmission settings<br>(Figure 6c-e). Conversely, we estimate that in low transmission settings with high DENV3 circulation, the<br>introduction of (Figure 6c-e). Conversely, we estimate that in low transmission settings with high DENV3 circulation, the introduction of Qdenga may increase DENV3 dominance, but in high transmission settings this effect is modest (Figure (Figure 6c-e). Conversely, we estimate that in low transmission settings with high DENV3 circulation, the introduction of Qdenga may increase DENV3 dominance, but in high transmission settings this effect is modest (Figure introduction of Qdenga may increase DENV3 dominance, but in high transmission settings this effect is modest (Figure 6d) and the number of DENV3 dominant periods over 20 years remains largely unchanged by vaccination (Figu modest (Figure 6d) and the number of DENV3 dominant periods over 20 years remains largely ditentinged<br>by vaccination (Figure 6f). Taken together, these results suggest that under the VI mode of vaccine action,<br>routine vacc by vaccination (Figure 6f). Taken together, these results suggest that under the VI mode of vaccine action,<br>routine vaccination would only minimally alter the serotype-specific dynamics that would be observed in<br>the absenc

#### **Discussion**

The absence of vaccination.<br>The serve of vaccination would only minimally alter the serve of the serve of the serotype-specific dynamics o<br>The series with alter that would be observed in the series that would be observed i Discussion<br>By combining a correlates-c<br>we show that Qdenga has  $\begin{array}{c} \n \downarrow \quad \quad \downarrow \quad \down$  We show that Qdenga has an efficacy profile and predicted public health impact that varies with age,<br>5<br>5 we show that  $\frac{d}{d}$  has an efficiency profile and profile public health impact that varies with age, serostatus, and infecting serotype. We estimate that Qdenga is highly protective against DENV2 regardless<br>of serostatus and moderately protective against the other three serotypes in seropositive individuals, with<br>evidence evidence of potential enhancement in disease risk following DENV3 and DENV4 infection in seronegative<br>subjects. Notably, we found that this risk is greatest in seronegative children aged 4-5 years at vaccination.<br>Despite t subjects. Notably, we found that this risk is greatest in seronegative children aged 4-5 years at vaccination.<br>Despite this imperfect efficacy profile, our estimates suggest that the introduction of Qdenga could<br>reduce the Subject this imperfect efficacy profile, our estimates suggest that the introduction of Qdenga could<br>reduce the burden of hospitalised dengue in high transmission intensity settings by up to approximately<br>20% over the firs Despite the burden of hospitalised dengue in high transmission intensity settings by up to approximately<br>20% over the first ten years of routine programmatic use. These findings support the recent WHO<br>recommendations on t

dengue disease burden and transmission<sup>22,27</sup>.<br>Qdenga VE estimates stratified by serotype and age have not yet been reported by the phase III trial<br>investigators<sup>14–18</sup>. However, our model-derived estimates agree with earl Example also are the use of Qdenga in children aged 6 years of age and above in settings with high<br>dengue disease burden and transmission<sup>22,27</sup>.<br>Qdenga VE estimates stratified by serotype and age have not yet been report dengue disease burden and transmission<sup>22,27</sup>.<br>Qdenga VE estimates stratified by serotype and age have not yet been reported by the phase III trial<br>investigators<sup>14-18</sup>. However, our model-derived estimates agree with ear (i\(・・・) Investigators<sup>14-18</sup>. However, our model-derived estimates agree with early clinical studies and previous<br>work on the functional immune response elicited by Qdenga which suggested that DENV2 is the<br>dominant replicating ser investigators<sup>24</sup>–<sup>24</sup>. However, our model-derived estimates agree with early clinical studies and previous<br>work on the functional immune response elicited by Qdenga which suggested that DENV2 is the<br>dominant replicating s dominant replicating serotype and driver of homotypic immunity<sup>19,20,28</sup>. We find that Qdenga protects against symptomatic disease and hospitalisation caused by DENV1, DENV3 and DENV4 in seronegatives aged 4-5 years for 3dominant replicating serotype and driver of homotypic immunity<sup>29,20,29</sup>. We find that Qdenga protects against symptomatic disease and hospitalisation caused by DENV1, DENV3 and DENV4 in seronegatives aged 4-5 years for 3 aged 4-5 years for 3-15 months, after which we estimate a potential risk of disease enhancement. In seronegative children aged 6-16 years, we estimate the initial period of partial protection to be at least 27 months. The aged 4-5 years for 3-15 years, we estimate the initial period of partial protection to be at least 27 months. The uncertainty around VE and potential risks for seronegative recipients highlight the need for continued moni served for the uncertainty around VE and potential risks for seronegative recipients highlight the need for continued monitoring of Qdenga's efficacy profile and collection of additional data in post-licensure studies<sup>23,</sup> continued monitoring of Qdenga's efficacy profile and collection of additional data in post-licensure<br>studies<sup>23,29</sup>, especially for DENV3 and DENV4. The use and timing of an additional booster dose is also<br>currently bein

currently being evaluated<sup>22</sup> and it will be important to assess whether an extra vaccine dose might<br>mitigate the potential risks that we have identified.<br>We cannot rule out a potential risk of enhancement in any seronega currently being evaluated<sup>22</sup> and it will be important to assess whether an extra vaccine dose might<br>mitigate the potential risks that we have identified.<br>We cannot rule out a potential risk of enhancement in any seronegat We cannot rule out a potential risk of enhancement<br>was higher and the risk of enhancement lower in ch<br>6, independent of their serostatus. Age-depende<br>Dengvaxia clinical trial data<sup>30,31</sup> and whilst the<br>understood, these r いしょう しょうしょう Was higher and the risk of enhancement lower in children over 6 years of age compared with those under<br>6, independent of their serostatus. Age-dependencies in VE were found also in the analysis of the<br>Dengvaxia clinical tr 6, independent of their serostatus. Age-dependencies in VE were found also in the analysis of the<br>Dengvaxia clinical trial data<sup>30,31</sup> and whilst the reasons for this age-dependency are not yet fully<br>understood, these res Foundary time and trial data<sup>30,31</sup> and whilst the reasons for this age-dependency are not yet fully understood, these results suggest reduced antibody and cell-mediated memory responses to vaccines in young children<sup>32,33</sup>

Dengvaxia clinical trial data<sup>30,31</sup> and whilst the reasons for this age-dependency are not yet fully understood, these results suggest reduced antibody and cell-mediated memory responses to vaccines in young children<sup>32,3</sup> understood, these results suggest reduced antibody and cell-mediated memory responses to vaccines in<br>young children<sup>32,33</sup>.<br>Our analysis shows that population impact and individual benefit/risk depend on setting-specific<br>t young children<sup>32,33</sup>.<br>Our analysis show<br>transmission intens<br>average impact in s<br>preventing DENV2<br>DENV3 and DENV4.<br>on average) the lo (しょりしょう The many setting of properties in the tend of the positive shows that all the setting, the average impact in seronegative individuals is positive but the positive impact is driven almost entirely by preventing DENV2 cases The positive impact is driven almost entirely preventing DENV2 cases and is counterbalanced by lower (and potentially negative) impacts against<br>DENV3 and DENV4. However, in higher transmission intensity settings (>60% sero preventing DENV2 cases and is counterbalanced by lower (and potentially negative) impacts against<br>DENV3 and DENV4. However, in higher transmission intensity settings (>60% seropositivity in 9-year-olds<br>on average), the low DENV3 and DENV4. However, in higher transmission intensity settings (>60% seropositivity in 9-year-olds<br>on average), the lower 95% credible bound on individual impact remains positive. Avoiding potentially<br>negative indivi on average), the lower 95% credible bound on individual impact remains positive. Avoiding potentially<br>negative individual impacts therefore requires Qdenga vaccination strategies tailored to local settings,<br>using recent f negative individual impacts therefore requires Qdenga vaccination strategies tailored to local settings,<br>using recent force-of-infection estimates<sup>34</sup> and optimised vaccination ages. Pre-vaccination screening<sup>35</sup> is<br>expec using recent force-of-infection estimates<sup>34</sup> and optimised vaccination ages. Pre-vaccination screening<sup>35</sup> is<br>expected to reduce the (already modest) population impact by about 30-80%, depending on the<br>transmission setti using recent force-of-infection estimates<sup>34</sup> and optimised vaccination ages. Pre-vaccination screening<sup>33</sup> is<br>expected to reduce the (already modest) population impact by about 30-80%, depending on the<br>transmission settin transmission setting and considering test limitations<sup>36</sup>, additional costs, logistical challenges, and the experience with Dengvaxia<sup>37</sup>, pre-vaccination screening for Qdenga is currently not recommended by WHO<sup>22</sup>.<br>WHO<sup></sup>

transmission setting and considering test limitations<sup>36</sup>, additional costs, logistical challenges, and the experience with Dengvaxia<sup>37</sup>, pre-vaccination screening for Qdenga is currently not recommended by WHO<sup>22</sup>.<br>WHO<sup>2</sup> experience with Dengvaxia<sup>37</sup>, pre-vaccination screening for Qdenga is currently not recommended by<br>WHO<sup>22</sup>.<br>In early 2024, Brazil became the first country to roll out Qdenga<sup>12</sup> and our estimates suggest that,<br>assuming 80 WHO<sup>22</sup>.<br>In early<br>assumin<br>95 (95%<br>vaccinat<br>effective ーミート In early 2024, Brazil became the first country to roll out Qdenga<sup>22</sup> and our estimates suggest that, assuming 80% coverage, in a high transmission setting (60% seropositive 9-year-olds) Qdenga could avert<br>95 (95% Crl: 25 assuming 80% crites 25 to 178) symptomatic cases and 14 (95% Crites 1-23) hospitalised cases, per 1,000 children vaccinated. Careful monitoring of the Brazilian programme will be important to evaluate programme effectivene 99 (1958 CRI: 25 to 179) symptomatic cases and 19 (1958 CRI: 178) subspectively per 1,900 children<br>vaccinated. Careful monitoring of the Brazilian programme will be important to evaluate programme<br>effectiveness, impact and vacancient vacancients of the Brazilian programme will be important to evaluate programme<br>effectiveness, impact and safety. effectiveness, impact and safety.

(ミノー(く) serotypes were approximately equally transmissible. However, during Qdenga's phase III trial, spanning<br>4.5 years across eight countries in Southeast Asia and South America, the four serotypes (DENV1, DENV2,<br>DENV3 and DENV4 1.5 years across eight countries in Southeast Asia and South America, the four serotypes (DENV1, DENV2, DENV3 and DENV4) accounted for 42.9%, 31.4%, 21.8%, and 3.9% of cases, respectively. If such patterns of serotype domi DENV3 and DENV4) accounted for 42.9%, 31.4%, 21.8%, and 3.9% of cases, respectively. If such patterns of serotype dominance continue in the future, the positive impact of Qdenga may be higher than estimated here. However, DENTIFY ACCOMBATE THE TRIM, THE TRIM, THE TRIM, THE TRIM, THE TRIM, THE TRIM OF SETUTE OF SETUTE OF SETUTE AND<br>DESTIMATED THE EXTINCT AND SETURE THE SETURE THAT ASSEMBLE THAT ASSEMBLE THAT ASSEMBLE THAT ASSEMBLE THAT ASSEM of serimated here. However, we note that DENV3 has recently re-emerged in several South American and Asian countries after its absence over several years, suggesting a need for caution in assuming that past serotype domina Asian countries after its absence over several years, suggesting a need for caution in assuming that past<br>serotype dominance trends will continue in the future. More generally, there is a need for better<br>characterising the Exercity and dominance trends will continue in the future. More generally, there is a need for better characterising the fundamental transmissibility and severity of the four serotypes. Critically, despite the estimated se servery the multimater of methods that means that transmissibility and severity of the four serotypes. Critically, despite the estimated serotype imbalance in efficacy, our modelling suggests that even widespread programma

characterising the fundamental transmission, and severity of the four severity positions, and the set imated serotype imbalance in efficacy, our modelling suggests that even widespread programmatic use<br>of Qdenga will at mo of Qdenga will at most cause minor changes in patterns of serotype dominance.<br>While modelling cannot substitute for the lack of data, our biologically motivated approach to VE<br>modelling allowed us to share model parameters surrogate marker for protection (or risk) from symptomatic and hospitalised dengue at the population ハード こくり けい modelling allowed us to share model parameters across strata, increasing statistical power. Although<br>absolute dengue correlates of protection are yet to be identified, our analysis indicates that mean<br>antibody titres kinet modelling allows also dengue correlates of protection are yet to be identified, our analysis indicates that mean<br>antibody titres kinetics can explain the efficacy of Qdenga, suggesting that neutralising titres are a<br>surrog antibody titres kinetics can explain the efficacy of Qdenga, suggesting that neutralising titres are a<br>surrogate marker for protection (or risk) from symptomatic and hospitalised dengue at the population<br>level<sup>5,6,10</sup>. Ho surrogate marker for protection (or risk) from symptomatic and hospitalised dengue at the population<br>level<sup>5,6,10</sup>. However, there are several limitations to our VE model. We needed to assume different<br>threshold titres for level<sup>5,6,10</sup>. However, there are several limitations to our VE model. We needed to assume different threshold titres for protection for seronegative and seropositive vaccine recipients, suggesting that qualitative differ qualitative differences in the humoral response and potentially other immune functions, such as cellular<br>immunity, can play an important role<sup>19,20,38</sup>. The lack of individual-level data meant that we could not<br>investigate immunity, can play an important role<sup>19,20,38</sup>. The lack of individual-level data meant that we could not investigate the link between individual antibody trajectories and vaccine induced protection, nor could we investiga investigate the link between individual antibody trajectories and vaccine induced protection, nor could we investigate how boosting of antibody titres due to subclinical infections and homotypic dengue re-<br>exposure during investigate how boosting of antibody titres due to subclinical infections and homotypic dengue re-<br>exposure during the phase III trial <sup>10</sup> affected our VE estimates. Furthermore, the use of hospitalisation as<br>a clinical e

The transmission model presented in this study can similarly be used to assess the potential impact of exposure during the phase III trial <sup>40</sup> affected our VE estimates. Furthermore, the use of hospitalisation as<br>a clinical endpoint (combined with the limited country-level data on hospitalisation protocols) limited the<br>ext extent to which we could account for different country-specific rates of severe dengue disease.<br>The VE model developed in our study can be easily adapted to estimate and compare the efficacy of other<br>dengue vaccines, such The VE model developed in our study can be easily adapted to estimate and compare the effica<br>dengue vaccines, such as the live-attenuated Butantan-DV vaccine currently being evaluated<br>The transmission model presented in t  $\frac{1}{2}$ The transmission model presented in this study can similarly be used to assess the potential impact of other dengue interventions and combinations of interventions, including new dengue vaccines, Wolbachia<sup>40</sup>, and antivir dengue vaccines, such as the live-attenuated Butantan-DV vaccine currently being evaluated in Brazil<sup>39</sup>.<br>The transmission model presented in this study can similarly be used to assess the potential impact of<br>other dengue The transmission model interventions and combinations of interventions, including new dengue vaccines,<br>Wolbachia<sup>40</sup>, and antivirals <sup>41</sup>, supporting the WHO recommendation to consider dengue vaccination as<br>part of an inte

Wolbachia<sup>40</sup>, and antivirals <sup>41</sup>, supporting the WHO recommendation to consider dengue vaccination as<br>part of an integrated strategy to control dengue<sup>22</sup>. It will be important to evaluate how combinations of<br>interventi part of an integrated strategy to control dengue<sup>22</sup>. It will be important to evaluate how combinations of interventions will affect transmission dynamics, and hence the impact of vaccination.<br>In conclusion, this study fin In conclusion, this study finds evidence of high efficacy of Qdenga vaccination agains<br>the other serotypes in seropositive individuals, resulting in modest reductions in<br>hospitalisations across different transmission inte |
| t<br>| c<br>| the other serotypes in seropositive individuals, resulting in modest reductions in dengue cases and<br>hospitalisations across different transmission intensity settings. Conversely, except for DENV2, we found<br>evidence for a p hospitalisations across different transmission intensity settings. Conversely, except for DENV2, we found<br>evidence for a potential risk of enhancement in seronegative individuals, especially in those aged 4-5<br>years at vacc evidence for a potential risk of enhancement in seronegative individuals, especially in those aged 4-5<br>years at vaccination. The analysis presented in this paper informed the recommendations recently<br>published in the WHO p years at vaccination. The analysis presented in this paper informed the recommendations recently<br>published in the WHO position paper<sup>22</sup> on dengue vaccination and demonstrates how modelling can help<br>translate clinical tria published in the WHO position paper<sup>22</sup> on dengue vaccination and demonstrates how modelling can help<br>translate clinical trial data and complex efficacy profiles into population impact estimates, thereby<br>optimising vaccina published in the WHO position paper<sup>22</sup> on dengue vaccination and demonstrates how modelling can help<br>translate clinical trial data and complex efficacy profiles into population impact estimates, thereby<br>optimising vaccina optimising vaccination deployment to minimise individual risk and maximise public health benefit.<br>
Therefore, thereby profiles into population is and maximise public health benefit. optimising vacanties individual risk and maximise individual risk and maximise public health benefit.<br>The new fit is defined to minimise public health benefit. The new fit is defined to minimize the new fit is de

### **Figures**



and hospitalisations in the phase III clinical trial by (a) trial arm and time, (b) age, serostatus, and trial arm and (c) serotype, serostatus, and trial arm. Note that the plotted resolution is lower than the data used in the model calibration. The modelled attack rates show the mean (triangle) and 95% Credible Interval (CrI, dashed line). The observed attack rates show the mean (circle) and 95% exact binomial confidence interval (solid line). (d) Estimated vaccine efficacy by serotype (columns), serostatus (rows), age group (colours), against symptomatic disease and hospitalisation (rows). The solid line represents the mean of the posterior distribution and the shaded area represents the 95% CrI. The dashed horizontal line marks 0 efficacy. VE in multitypic individuals is shown in Supplementary Figure 8. SN: seronegative. SP: seropositive. V: vaccine arm. P: placebo arm.



Figure 2: Population-level impact of vaccination. Cumulative proportion of hospitalised and symptomatic cases averted over 10 years (y-<br>axis) by transmission setting (x-axis, expressed as the average seroprevalence in 9-ye disease (VI, blue) or only against disease (VS, pink) decaying for 15 years (D15), using 80% coverage across ten years and the Brazilian disease (VI, blue) or only against disease (VS, pink) decaying for 15 years (D15), using 80% coverage across ten years and the Brazilian demography (a) over all serotypes and (b) by serotype. The solid line represents the mean, the shaded regions represent the 95% credible interval.



Figure 3: Impact of age at vaccination on the population-level impact by transmission setting. Cumulative proportion of hospitalised and symptomatic cases averted (rows) by transmission setting (x-axis, expressed as the average seroprevalence at 9-year-old), and vaccine mechanism (columns) assuming vaccination of ages 6-12 (y-axis) and the Brazilian demography, over ten years. VI\_D15: scenario assuming efficacy against infection and disease decaying for 15 years post vaccination. VS\_D15: scenario assuming efficacy against disease decaying for 15 years post vaccination.



Figure 4: Individual-level impact of vaccination. Proportion of hospitalised and symptomatic cases averted (columns) in the first vaccinated cohort of 6-year-olds over ten years by transmission setting, expressed as the average seroprevalence at 9-year-old (x-axis) assuming a vaccination coverage of 80% using model VS\_D15 (efficacy against disease decaying for 15 years post vaccination) and the<br>Brazilian demography. The impact is shown overall (all) and among baseline seropositive an Brazilian demography. The impact is shown overall (all) and among baseline seropositive and seronegative vaccinees (rows). The solid lines represent the mean, light shading represents the overall uncertainty (95% CrI), and the dark shading represents the parameter uncertainty (95% CrI).



Figure 5: Cases averted by vaccination per 1,000 vaccinated children. Absolute number of symptomatic cases and hospitalisations<br>(columns) averted over 10 years post second dose (y-axis) in the first vaccinated cohort of 6by transmission setting, expressed as the average seroprevalence in 9-year-olds (x-axis), assuming model VS\_D15 (efficacy against disease by transmission setting, expressed as the average seroprevalence in 9-year-olds (x-axis), assuming model VS\_D15 (efficacy against disease decaying for 15 years post vaccination), the Brazilian demography and that 9% of symptomatic cases are hospitalised. (a) Cases averted in the entire vaccinated cohort (all, blue), and among baseline seropositive (green) and baseline seronegative (pink) vaccinees and (b) cases averted by serotype (colours) and serostatus (rows). The bars represent the mean, and the error bars represent the overall uncertainty (95% CrI).



Figure 6: Impact of vaccination on serotype dynamics. For the 1,000 simulations with the lowest DENV2 burden (a, c, e) and the highest DENV3 burden (b, d, f), across transmission settings (sp9, average seroprevalence in 9-year-old) with (VI) and without (NV) vaccination we<br>show (a-b) example serotype-specific transmission dynamics (c-d) the mean proportio show (a-b) example serotype-specific transmission dynamics (c-d) the mean proportion of time each serotype is dominant and (e-f) the proportion of simulations (y-axis) in which DENV2 (e) and DENV3 (f) become the dominant serotype for the specified number of seasons (colours), over a 20 year period since the start of vaccination.

#### Data availability

All data used in the modelling study are on GitHub at https://github.com/bnc19/qdenga\_impact.

#### Code availability

Code is available at: https://github.com/bnc19/qdenga\_impact.

#### Acknowledgments

ID acknowledges funding from Wellcome Trust (213494/Z/18/Z). NMF, BCD and ID acknowledge funding<br>from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. NMF also acknowledges funding by the National Institute for Health and Care EDCTP3 Joint Undertaking. NMF also acknowledges funding by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Modelling and Health Economics, a partnership in Modelling<br>Extense the UIF Used the Central Association of the College Lender and Hell TM (search each MUID 2000 between the UK Health Security Agency, Imperial College London and LSHTM (grant code NIHR200908), and from the Jameel Institute provided by a philanthropic donation by Community Jameel. Disclaimer: "The views expressed are those of the author(s) and not necessarily those of the NIHR, UK Health Security Agency or the Department of Health and Social Care."

#### Online Methods

Data<br>Published phase III clinical trial data are available for  $12^{14}$ ,  $18^{15}$ ,  $24^{16}$ ,  $36^{17}$ , and 54 months<sup>18</sup> post-30 days after the second dose endpoints. From these publications, we extracted the number of symptomatic VCD cases ( $N_{symp}$ ) and the number of VCD cases leading to hospitalisation ( $N_{hosp}$ ) at the finest stratification available. Case data were obtained by trial arm  $v$  (1 = placebo, 2 = vaccinated), and by baseline serostatus<br>h (- = seronegative + = seronositive) infecting serotyne k (DENV1 to DENV4) and age group i (1 = 4-5vrs b (- = seronegative, + = seropositive), infecting serotype  $k$  (DENV1 to DENV4) and age group  $j$  (1 = 4-5yrs,<br>2 = 6-11vrs. 3 = 12-16vrs), within each reporting interval  $d$  (1 = 1-12 months, 2 = 13-18 months, 3 = 19-24 2= 6-11yrs, 3 = 12-16yrs), within each reporting interval d  $(1= 1-12$  months, 2 = 13-18 months, 3 = 19-24 months,  $4 = 25-36$  months,  $5 = 37-48$  month,  $6 = 49-54$  months), as published. As only the first VCD case in each trial participant is reported in the phase III trial publication, we right-censored cases at the end of each reporting interval d. See SI Section 1 for a complete overview of the data. each reporting interval a. See SI Section 1 for a complete overview of the data.<br>Cobort supplyed model of  $V\mathsf{E}$ 

#### Cohort survival model of VE

To estimate VE, we calibrated a Bayesian cohort survival model to the above data (Supplementary Figure<br>1a). We assumed an individual may be infected up to four times, and any infection could be symptomatic. We did not track further infections among individuals who had a detected infection. The model was solved at monthly time intervals  $(t = 1$  to 54).

### Fitting the initial conditions  $\frac{1}{1}$

Let  $p_{ki}$  denote the probability of exposure to serotype  $k$  (= 1,2,3,4) in age group j prior to the start of the trial  $(T_0)$  and let c denote the number of serotypes an individual had been exposed to  $(= 0, 1, 2, 3, 4)$ .

The probability that an individual has been exposed to serotypes  $\Omega$  within seth<sub>c</sub>, defined as  $h_0 = \{\emptyset\}$ ,  $\overline{a}$  $h_1 = \{(1), (2), (3), (4)\},$ <br>  $h_2 = \{(1,2), (1,3), (1,4)\},$ <br>  $h_3 = \{(1,2), (1,3), (1,4)\}$  $h_2 = \{ \{1,2\}, \{1,3\}, \{1,4\}, \{2,3\}, \{2,4\}, \{3,4\} \},$  $h_3 = \{\{1,2,3\}, \{1,2,4\}, \{1,3,4\}, \{2,3,4\}\}$  and  $h_4 = \{\{1,2,3,4\}\}\$  is given by:  $pE_{\Omega}(j, T_0) = \prod_{k \in \Omega} p_{kj} \prod_{k' \notin \Omega} (1 - p_{k'j})^{\#(\Omega)}$  $\prod_{k\in\Omega} P_{kj} \prod_{k'\notin\Omega} (1 - P_{k'j})$ 

Accounting for the imperfect test sensitivity and specificity of the microneutralisation test used to classify  $\frac{1}{1}$ individuals as seronegative  $(-)$  or seropositive  $(+)$  at baseline <sup>42</sup> (see SI Sections 2.1 and 2.2 for full details). The probability of being classified as seropositive at baseline is: individuals as seronegative (–) or seropositive (+) at baseline  $4\overline{4}$  (see SI Sections 2.1 and 2.2 for full<br>details), the probability of being classified as seropositive at baseline is:<br>(4)  $\left( \begin{array}{ccc} 4 \end{array} \right)$ 

$$
pSP(j, T_0) = (1 - spec) pE_0(j, T_0) + sens \left(\sum_{c=1}^{4} \sum_{\Omega \in h_c} pE_{\Omega}(j, T_0)\right) \#(2)
$$

 $\overline{a}$ י<br>ו We estimate  $pSP(j, T_0)$  by fitting the number of baseline seropositive individuals by age group *j* across<br>both trial arms,  $N_{SP}(j, T_0)$  to the observed data, assuming a Binomial distribution and the observed<br>number of par number of participants  $N_{pop}(j, T_0)$  in age group j over both the vaccine and placebo arms:

$$
N_{SP} (j, T_0) \sim Binomial \left( N_{pop} (j, T_0), pSP(j, T_0) \right) \#(3)
$$

 $\frac{1}{\sqrt{2}}$ 

Estimating vaccine efficacy<br>We used a modified form of the correlates of protection model first proposed by Khoury *et al.<sup>24</sup>* (to model VE for SARS-CoV-2 vaccines) to link the imputed neutralising antibody titre  $n_{ck}(t)$  against serotype k  $V = \frac{1}{\sqrt{2}}$  vaccines) to link the imputed neutralising antibody titre ( against series) to link the imputed neutralising and  $\frac{1}{\sqrt{2}}$ 

(Supplementary Figure 3) with the risk ratio (comparing vaccinated and divaccinated individuals) of symptomatic disease  $RR_{symp}$ <sub>cvkj</sub> $(t_i)$  and hospitalisation  $RR_{hosp}$ <sub>cvkj</sub> $(t)$ :

$$
RR_{symp_{cvkj}}(t) = \frac{1 + L_{ck}}{1 + \left(\frac{n_{ck}(t)}{e^{\beta_{symp_{j}}} * n_{50_{cks}}}\right)^{w_{ck}}}
$$
 if  $v = 2 \#(4)$ 

 $\frac{1}{2}$ **SI Section 2.3.** By definition,  $RR_{symp}$ <sub>cvkj</sub> = 1 if  $v = 1$ . Here  $L_{ck}$  is the maximum potential vaccine-<br>induced disease enhancement with exactive a secondated with vaccination. This is assumed to be associated SI Section 2.3. By definition,  $\frac{SN_{sym}}{P_{cvk}} = 1 + \frac{1}{2} = 1$ . Here  $E_{ck}$  is the maximum potential vaccine-<br>induced disease enhancement with serotype k associated with vaccination. This is assumed to be zero for all individuals with one or more previous DENV exposures ( $1 \leq c \leq 4$ ), such that the maximum RR<sub>svmn</sub> is all for all baseline seropositive vaccinees. We estimate  $L_{ck}$  ( $\geq$ 0) for vaccinated individuals with no prior<br>DENV exposure (c = 0), such that their maximum RR------- may be >1. The parameter  $n_{\rm sc}$  , represents DENV exposure  $(c = 0)$ , such that their maximum RR<sub>symp</sub> may be >1. The parameter  $n_{50_{cls}}$  represents the neutralising titre conferring 50% protection against disease (in the absence of enhancement) for the oldest age group ( $i = 3$ ), which is scaled by  $e^{\beta_{symp_j}}$  for individuals in the younger age groups,  $j \in \{1,2\}$ . oldest age group ( $j = 3$ ), which is scaled by  $e^{Psymp}j$  for individuals in the younger age groups,  $j \in \{1,2\}$ .<br>Finally,  $w_{ck}$  controls the steepness of the relationship between neutralising titre and the risk ratio. No that since  $RR_{symp}$  is dependent on the cumulative number of DENV exposures at month t, not the that since  $\frac{1}{2}$  is dependent on the cumulative number of  $\frac{1}{2}$  in the cumulative in the complete  $\frac{1}{2}$  is dependent on the cumulative number of exposures prior to vaccination, we are assuming that the order o does not matter. So, for example, a baseline monotypic vaccinee escaping infection up to month t has the same disease risk as a baseline seronegative vaccinee with a single breakthrough infection prior to month  $t$ . same disease risk as a baseline serongative vaccine vaccinee with a single breakthrough infection prior to month<br>t.

We assume that the vaccine induced neutralising antibody titres are characterised by an initial period of  $\frac{1}{1}$ fast decay, with half-life  $h s_h$  (decay rate  $\pi 1_h = -\ln(2) / \ln(h s_h)$ ), followed by a period of slow decay with half-life  $hl$  (decay rate  $\pi/2 = -\ln(2) / \ln (hl)$ ):

$$
n_{bk}(t) = n_{0_{bk}} \frac{e^{(\pi 1_b t + \pi_2 t s_b)} + e^{(\pi 2 t + \pi 1_b t s_b)}}{e^{(\pi 1_b t s_b)} + e^{(\pi 2 t s_b)}} \#(5)
$$

 $\overline{a}$ Vaccination ( $b \in \{-, +\}$ ),  $ts_b$  is the time at which decay switches from fast to slow, and t is the month elapsed since the second dose  $v^2$  and  $v^2$  is the second dose.

## elapsed since the second dose.<br>Like lihood  $\frac{1}{\sqrt{2}}$

<u>Likelihood</u><br>Within each trial reporting period  $d$ , we assume a constant serotype-specific FOI over time,  $\lambda_k(d)$ . As the model is solved at monthly intervals t, we set  $\lambda_k(t) = \lambda_k(d)$  for all months t within the reporting period d.  $d.$ 

For each month t, we calculate the probability of surviving that month without infection, given as  $\frac{1}{6}$  $\frac{e^{-\sum_{k\in\Omega}\lambda_k(t)}}{2E_{\Omega_k}(t)}$  (Supplementary Figure 1a). The probability of being seronegative at the start of month  $t+1$ <br>is therefore:<br> $pE_{\Omega_{k-1}}(j,t+1) = e^{-\sum_{k=1}^4\lambda_k(t)} pE_{\Omega_{k-1}}(j,t) \#(6)$ 

$$
pE_{\emptyset_{bv}}(j,t+1) = e^{-\sum_{k=1}^{4} \lambda_k(t)} pE_{\emptyset_{bv}}(j,t) \#(6)
$$

 $P_{\mu}U_{\mu}U_{\nu}U_{\nu}$ ,  $\mu$ , 5<br>} the sum of those who were already exposed to the serotype combination in set Ω and who escaped<br>infection by all serotypes not in Ω during month t, plus those with previous exposure to all serotypes in set  $\Omega$  excluding serotype k (denoted  $\Omega_{\chi k}$ ) who had an undetected infection to serotype k during month infection by all servers previous names not in plus the contract monopole in previous to all serotypes in  $\Omega$  excluding serotype k (denoted  $\Omega_{\backslash k}$ ) who had an undetected infection to serotype k during month  $t-12$  (a set *Ω* excluding serotype *k* (denoted  $\Delta \chi_k$ ) who had an undetected infection to serotype *k* during month<br>*t* – 12 (assuming a 12-month period of heterotypic cross-immunity and censoring individuals with<br>detected infe detected infections following the date of detection<sup>20,21</sup>):<br>detected infections following the date of detection<sup>20,21</sup>):

$$
pE_{\Omega bv}(j, t+1) = e^{-\sum_{k \in \Omega} \lambda_k(t)} pE_{\Omega bv}(j, t) + \sum_{k \in \Omega} \Big(1 - RR_{symp} (t-12) p_{symp_{ck}} \Big) \Big(1 - e^{-\lambda_k(t-12)} \Big) pE_{\Omega_{\setminus k} bv}(j, t-12) \#(7)
$$

where the  $(1 - e^{-\lambda_k (t-12)}) p E_{\Omega_{\backslash k} b\nu}(j, t-12)$  is the incidence of infection with serotype *k* during month<br>  $t - 12$  in individuals previously exposed to all serotypes in set  $\Omega$  excluding *k*. The probability of  $\int P E$ 

developing symptoms upon infection is denoted  $p_{symp_{ck}}$ . The second term in equation 7 represents the incidence of asymptoms upon infection 12 months prior let  $y =$  the probability of symptoms during a the incidence of asymptomatic infection 12 months prior. Let  $\gamma$  = the probability of symptoms during a the incidence of asymptomatic infection 12 months prior. Let  $\gamma$  = the probability of symptoms during a<br>secondary infection,  $\rho_k$  = the serotype-specific risk of symptoms during a primary infection relative<br>to a seconda to a secondary infection and  $\varphi$  = the risk of symptomatic disease during a post-secondary infection compared to a primary infection. Thus,  $p_{symp}$ <sub>ck</sub> –  $p_k$   $\gamma$  for primary infections  $(c - 0)$ , –  $\gamma$  for secondary infections  $(c = 1)$ , and $= p_k \not\in \varphi$  for post-secondary infections  $(z \leq c \leq s)$ .<br>The incidence of infection is:

֖֚֚֚֬  $\frac{1}{2}$  include of interaction is:

$$
Inc_{\Omega bvk}(j, t) = (1 - e^{-\lambda_k(t)}) * \sum_k p E_{\Omega_{\setminus k} bv}(j, t) \# (8)
$$
  
and hospitalisation are:

$$
Symp_{\Omega bvk}(j, t) = p_{symp_{ck}}RR_{symp_{cvkj}}(t)lnc_{\Omega bvk}(j, t) \#(9)
$$

$$
Hosp_{\Omega bvk}(j, t) = p_{hosp_{ck}}p_{symp_{ck}}RR_{hosp_{1vk}}(t)lnc_{\Omega bvk}(j, t) \#(10)
$$

Here  $p_{hosp_{ck}}$  is the probability of hospitalisation. Let  $\delta_k =$  the probability that a symptomatic case due to Serotype k is hospitalised and  $\epsilon$  = the risk of hospitalisation in secondary cases, compared to primary or<br>post-secondary infections. Thus,  $p_{hasm} = \delta_k \epsilon$  when  $c = 1$ , and  $\delta_k$  otherwise. See SI Section 2.4 for post-secondary infections. Thus,  $p_{hosp_{ck}} = \delta_k \epsilon$  when  $c=1$ , and  $\delta_k$  otherwise. See SI Section 2.4 for<br>additional details on the incidence calculations. additional details on the incidence calcu<br>additional details on the incidence calcu  $-6k$  when  $k = 1$ , and  $6k$  otherwise. See SI Section 2.4 for

Summing over the serotype combinations, the total symptomatic case and hospitalisation incidence are:  $\ddot{\phantom{0}}$ 

$$
Symp_{bvk}(j, t) = \sum_{\Omega} Symp_{\Omega bvk}(j, t) \# (11)
$$

$$
Hosp_{bvk}(j, t) = \sum_{\Omega} Hosp_{\Omega bvk}(j, t) \# (12)
$$

The monthly symptomatic and hospitalisation incidences are aggregated to match the months within each trial reporting period  $d$ , and the expected number of symptomatic and hospitalised cases are calculated as: each trial reporting period in and the expected number of symptomatic and hospitalised cases<br>calculated as:

$$
S_{bvk}(j, d) = Symp_{bvk}(j, d) N_{surv_v}(j, d) \# (13)
$$
  
H<sub>bvk</sub>(j, d) =  $Hosp_{bvk}(j, d) N_{surv_v}(j, d) \# (14)$ 

where  $N_{surv_n}(j, d)$  is the observed population size in reporting period d, accounting for censoring of symptomatic cases in the previous time intervals. The observed total number of symptomatic cases and hospitalisations at time interval  $d$  are assumed to follow Binomial distributions:

$$
N_{symp}(d) \sim Binomial\left(N_{surv}(d), pS(d)\right) \#(15)
$$
  

$$
N_{hosp}(d) \sim Binomial\left(N_{surv}(d), pH(d)\right) \#(16)
$$
  
where  $pS(d) = \sum_{b} \sum_{v} \sum_{k} \sum_{j} S_{bvk}(j, d) / N_{surv}(d)$  and  $pH(d) = \sum_{b} \sum_{v} \sum_{k} \sum_{j} H_{bvk}(j, d) / N_{surv}(d)$ .

where  $P^2(x) = \sum_{b=0}^{n} \sum_{b=0}^{n} \sum_{k=0}^{n} \sum_{j=0}^{n} \sum_{k=0}^{n} \sum_{j=0}^{n} \sum_{k=0}^{n} \sum_{k=0}^{n} \sum_{j=0}^{n} \sum_{k=0}^{n} \sum_{j=0}^{n} \sum_{k=0}^{n} \sum_{j=0}^{n} \sum_{k=0}^{n} \sum_{k=0}^{n} \sum_{j=0}^{n} \sum_{k=0}^{n} \sum_{j=0}^{n} \sum_{k=0}^{n} \sum_{j=0}^{n} \sum_{k=0}^{$  $\overline{a}$ by age group, baseline serostatus, and trial arm; and by serotype and age group are all assumed to follow by age group, baseline serostatus, and trial arm; and by serotype and age group are all assumed to follow.<br>multinomial distributions (see SI Section 2.5 for details). multinomial distributions (see SI Section 2.5 for details).

# $\overline{1}$

Model variants and sensitivity analyses<br>To explore whether the data supported varying parameters by baseline serostatus, serotype, outcome, and age group, we considered multiple simpler nested models than those outlined above. Model variants were compared visually and quantitatively via the log-likelihood and the expected log-predictive density, estimated using the Watanabe–Akaike information criterion, to find the most parsimonious, biologically-<br>motivated model which could reproduce the trial data. Additionally, we tested fitting our final model to simulated data to confirm the identifiability of our model parameters (see SI Section 2.6 for details).<br>Specifically, we sampled each model parameter 20 times from distributions wider or centred away from Specifically, we sampled each model parameter 20 times from distributions wider or centred away from the priors (Supplementary Table 2). We also generated simulated case data to reconstruct the posterior distribution of the parameters which was compared to the true (known) parameter value. We also conducted sensitivity analysis on the enhancement assumption by testing a model variant with no vaccine conducted sensitivity analysis on the enhancement assumption by testing a model variant with no variant associated enhancement in seronegatives  $(L_{ck} = 0$  for all vaccinated individuals). SI Section 2.7 provides full detai associated enhancement in seronegatives ( $E_{ck} = 0$  for all vaccinated individuals). SI Section 2.7 provides full details on the sensitivity analyses run. full details on the sensitivity analyses run.<br>Inferential framework

# $\frac{1}{2}$

The model was fitted to the baseline seropositivity data ( $N_{SP}$ ) and number of VCD symptomatic ( $N_{sym}$ ) and hospitalised  $(N_{hosp})$  cases observed across the trial, stratified by baseline serostatus, age and<br>serotyne within a Bavesian framework. Parameter inference was carried out using the Hamiltonian Monte serotype within a Bayesian framework. Parameter inference was carried out using the Hamiltonian Monte<br>Carlo algorithm and the No-U-Turn sampler via Stan, a probabilistic programming language implemented Carlo algorithm and the No-U-Turn sampler via Stan, a probabilistic programming language implemented<br>Via the RStan package<sup>22</sup> (version 2.26.21) in R<sup>23</sup> (version 4.2.2). Four chains were run for 10.000 iterations Via the RStan package<sup>22</sup> (version 2.26.21) in R<sup>23</sup> (version 4.2.2). Four chains were run for 10,000 iterations<br>Lach, and we discarded the first 5.000 iterations as burn-in. Convergence was assessed visually and using each, and we discarded the first 5,000 iterations as burn-in. Convergence was assessed visually and using the  $\hat{R}$  statistic<sup>43</sup>. The estimated parameters, priors and their sources are listed in **Supplementary Table 2**. the *R* statistic<sup>to</sup>. The estimated parameters, priors and their sources are listed in **Supplementary Table 2**.<br>Transmission Model

#### Transmission Model

To evaluate the population-level impact of  $R_1$  is applied the vaccine efficiency estimates vacancies above to a 4-serotype stochastic compartmental model of dengue transmission, a deterministic version of which was publ above to a 4-serotype stochastic comparimental model in analysis in the model includes mosquito which was published in Ferguson *et al.*<sup>3</sup> (Supplementary Figure 1b). The model includes mosquito population dynamics with a which was published in Ferguson *et al.*" (**Supplementary Figure 1b**). The model includes mosquito<br>population dynamics with a seasonally varying carrying capacity. It models primary to quaternary human<br>infections, assuming infections, assuming that homotypic immunity is lifelong and heterotypic immunity is temporary (12 months). It tracks the serotype-specific infection history but not the order of past infections. The model is stratified by vaccine status, serostatus, and age, with single age classes for the first 20 years and 10 years thereafter. See the SI Section 3 for full details of the model. The model incorporates realistic non-<br>stationary human demography, calibrated to the demographic estimates for Brazil and the Philippines thereafter. See the SI Section 3 for full details of the model. The model incorporates realistic non-<br>stationary human demography, calibrated to the demographic estimates for Brazil and the Philippines<br>published in the UN published in the UN World Population Prospects 2022<sup>44</sup>. For this study, we embedded the VE model<br>detailed above into this transmission model. detailed above into this transmission model.<br>We explore four hypotheses about vaccine mechanism of action, obtained by combining (a) two

۱<br>ا hypotheses on the type of protection offered by the vaccine - only against disease (VS), parameterised from the survival model above, or also against infection (VI); (b) two assumptions for the period over which VE would wane, namely 5 years (approximately the period of the phase III trial) or 15 years (extrapolating beyond the trial). Full details on assumptions for the VI scenario are given SI Section 2.3. For each mechanism of action, we simulated the impact of routine vaccination of 6- to 12-year-olds across nine transmission intensity settings expressed in terms of average seroprevalence at nine years old (from 10% to 90% in steps of 10%). We assumed that all serotypes have near-identical transmissibility. We varied the vaccination coverage from 20% to 80% in steps of 20%. For each transmission setting, coverage scenario, and vaccine mechanism of action, we drew 200 samples from the posterior distribution of the parameters of the VE model and ran 50 stochastic simulations for each such posterior sample, giving parameters of the VE model and ran 50 stochastic simulations for each such posterior sample, giving

10,000 simulations per scenario in total (Supplementary Figure 1b). We summarise uncertainty in two<br>ways. The first is the overall uncertainty, calculated over the 10,000 realisations, which represents uncertainty in both the posterior parameter estimates and the stochastic simulations. The second is the parameter uncertainty, calculated as the uncertainty of the mean of the 50 stochastic simulations for each of the 200 posterior samples. parameter uncertainty, calculated as the uncertainty of the mean of the 50 stochastic simulations for each of the 200 posterior samples.

To estimate the impact of vaccination, we compare the disease burden of each model run with a  $\overline{\phantom{a}}$ counterfactual simulation where we assume zero VE. Notably, for each realisation we matched exactly the counterfactual and vaccine scenario (i.e. the dengue dynamics up to the point of vaccine introduction are the same). We define the individual-level impact of vaccination as the proportion of cases averted in the first vaccinated cohort, and the population-level impact as the proportion of cases averted in the entire population (including non-vaccinated individuals) (Supplementary Figure 1b) after 10 years of vaccination, which we assumed started from 2024. vacuument, which we assumed started from 2024.<br>References

### References

 $\ddot{\phantom{0}}$ 1. Halstead, S. & O'Rourke, E. Dengue viruses and mononuclear phagocytes. I. Infection<br>1. enhancement by non-neutralizing antibody. J. Exp. Med. 146, 201–217 (1977).<br>2. Sridhar, S. et al. Effect of dengue serostatus on den

2. Sridhar, S. et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327–340 (2018).

3. Ferguson, N. M. et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment. Science 353, 1033-1036 (2016). 3. Ferguson, N. M. et al. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal

deployment. Internal of the science 358, 929–932 (2017).<br>Science 358, 929–932 (2017).

Science 358, 929–932 (2017).<br>5. Salje, H. et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature 557, 719–723 (2018).

6. Katzelnick, L. C., Montoya, M., Gresh, L., Balmaseda, A. & Harris, E. Neutralizing antibody titers risk. Nature 557, 719–723 (2018). F. Katzelnick, L. C., Montoya, M., E. C., E., E., Balmaseda, A. & Harris, E. Neutralizing antibody title<br>against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Prod<br>Natl. Acad. Natl. Acad. Sci. 113, 728–733 (2016).<br>T. Pass S. et al. Protection against symptomatic dengue infection by neutralizing antibodies varies by

infection history and infecting serotype. Nat. Commun. 15, 382 (2024). 7. Bos, S. et al. Protection against symptomatic angularities in production against since these cyclinfection<br>18. Salie. H. et al. Variability in dengue titer estimates from plaque reduction neutralization tests

infection history and infecting servery per can be communities, see (2024).<br>8. Salje, H. et al. Variability in dengue titer estimates from plaque<br>poses a challenge to epidemiological studies and vaccine development. poses a challenge to epidemiological studies and vaccine development. PLoS Negl. Trop. Dis. 8, 8–10<br>(2014).

9. Moodie, Z. et al. Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J. Infect. Dis. 217, 742-753 (2018). erials in Asia and Latin America. J. Infect. Dis. 217, 742–753 (2018).<br>10. Salie. H. et al. Evaluation of extended efficacy of Dengyaxia vaccine against symptomatic and

thals in Asia and Latin America. J. In Asia and L. I. I<br>Subclinical dengue infection. Nat. Med. 27. 1395–1400 (2021). 10. Salje, H. et al. Evaluation of extended efficacy of Dengvaxia vaccine against symptomatic and

subclinical development and regulator<br>11. Nationalive infection. National development and regulator<br>111-eneration live attenuated dengue vaccines. Vaccine 36. 3411

und the vannices.<br>12. Alves, L. Brazil to start widespread dengue vaccinations. The Lancet 403, 133 (2024).<br>13. Alvanio. J. E., Partidos. C. D., Wallace. D. & Stinchcomb. D. T. Development of a recombinant.

12. Alves, L. Brazil to start widespread dengue vaccinations. The Lancet 403, 133 (2024).<br>13. Osorio, J. E., Partidos, C. D., Wallace, D. & Stinchcomb, D. T. Development of a recombinant,<br>chimeric tetravalent dengue vaccin  $\sim$  Chimeric tetravalent dengue vaccine candidate. Vaccine 33, 7112–7120 (2015).<br>14. Biswal. S. et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents.

chimeric tetrace of a tetravalent dengue vaccine in healthy child<br>Engl. J. Med. 381, 2009–2019 (2019). 14. Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N<br>Engl. J. Med. 381, 2009–2019 (2019).<br>15. Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in h

English them also prove them also provided.<br>15. Biswal, S. et al. Efficacy of a te<br>randomised. placebo-controlled. phas 15. Biswal, S. et al. Efficacy of a tetravalent dengue vaccine in health, children aged 4–16 years: a<br>randomised, placebo-controlled, phase 3 trial. The Lancet 395, 1423–1433 (2020). randomised, placebo-controlled, phase 3 trial. The Lancet 395, 1423–1433 (2020).

16. López-Medina, E. et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and<br>adolescents 2 years after vaccination. J. Infect. Dis. 225, 1521–1532 (2022).<br>17. Rivera, L. et al. Thre

17. Rivera, L. et al. Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003).<br>Clin. Infect. Dis. 75, 107–117 (2022).

18. Tricou, V. et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year Content of the Clint. The Clint.<br>18. Tricou, V. et al. Long-term effect.<br>The Sults from a phase 3. randomised. 18. Tricou, Tricou, V. et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-004): 1-year<br>18. Tricou, S. P. Long-term efficiency and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year-<br>18. Trico

e270 (2024).<br>19. White, L. J. et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced  $\begin{array}{ccc} 19. & \text{Whit} \ \text{by a live after} \end{array}$ 19. White, L. J. et al. Defining levels of dengue virus serotype-specific neutralizing antibodies induced

20. Waickman, A. T. et al. Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003. Front. Immunol. 10, (2019).<br>21. Tricou, V. et al. Characterization of the cell-mediated immune response to Takeda's live-

21. Tricou, V. et al. Characterization of the cell-mediated immune response to Takeda's live-<br>attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled 21. Tricou, Tricou, V. et al. Characterization of the characterization of the cell-mediated immune response to<br>1992. – M. W. W. H. O. Position Paper on Dengue Vaccines – May 2024, 203–224.<br>1993. – W. H.O. W. H. O. Position

22. WHO. WHO Position Paper on Dengue Vaccines - May 2024. 203–224

https://iris.who.int/bitstream/handle/10665/376641/WER9918-eng-fre.pdf (2024).<br>23. WHO. Meeting of the Strategic Advisory Group of Experts on Immunization.

WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, September 2023: Conclusions and Recommendations. https://iris.who.int/bitstream/handle/10665/374327/WER9847-eng-<br>fre.pdf?sequence=1 (2023).

24. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from fre.pdf?sequence=1 (2023).  $\frac{2}{3}$ . Symptomatic SARS-CoV-2 infection. Nat. Med. 2021 277 27, 1205–1211 (2021).<br>25. El Hindi. T. et al. Estimated efficacy of TAK-003 against asymptomatic dengue infection in childre

25. El Hindi, T. et al. Estimated efficacy of TAK-003 against asymptomatic dengue infection in children<br>and adolescents. (2023).

26. Medina, F. A. et al. Comparison of the Sensitivity and Specificity of Commercial Anti-Dengue Virus ر<br>26. Medina, F. A. et<br>lgG Tests to Identify Perso lgG Tests to Identify Persons Eligible for Dengue Vaccination. 2024.04.19.24306097 Preprint at<br>https://doi.org/10.1101/2024.04.19.24306097 (2024).

https://doi.org/10.1101/2024.04.19.24306097 (2024).<br>27. WHO SAGE. Background Paper on Dengue Vaccines. https://doi.org/10.1101/2024.04.19.24306097 (2024).

27. Who save save same vacant separation of the same values.<br>https://terrance.who.int/mediacentre/data/sage/SAGE\_eYB\_<br>28. Osorio. J. F. et al. Safety and immunogenicity of a rec

28. Osorio, J. E. et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-<br>controlled, phase 1 study. Lancet Infect. Dis. 14, 830–838 (2014).

dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 14, 830–838 (2014). recommendations on vaccines against dengue, respiratory syncytial virus, and issues statement on ongoing use of COVID-19 vaccines - PAHO/WHO. https://www.paho.org/en/news/11-1-2024-paho-<br>technical-advisory-group-tag-immunization-provides-regional-recommendations (2023).

ongoing use of COVID-1<br>19 vaccines - Laydon, D. J. et al. Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian sur<br>19 variation - Paholine III data elife 10, e65131 (2021). analysis of individual-level phase III data. eLife 10, e65131 (2021).<br>31. Dorigatti. I. et al. Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using

analysis of individual and the individual of the Sanofi level phase III data. e.g.<br>Individual-level phase III data. Commun. 9. 3644 (2018).

machine learning. Nat. Commun. 9, 3644 (2018).<br>32. Flanagan, K. L., Burl, S., Lohman-Payne, B. L. & Plebanski, M. The challenge of assessing infant on<br>22. Flanagan, K. L., Burl, S., Lohman-Payne, B<br>vaccine responses in resource-poor settings. Fxpe yaccine responses in resource-poor settings. Expert Rev. Vaccines 9, 665–674 (2010).<br>33. Tappero, J. W. et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococca

33. Tappero, J. W. et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA 281, 1520–1527 (1999).<br>34. Cattarino, L., Rodriguez-Barraquer, I., Imai, N., Cummings, D. A. T. & Ferguson, N. M. Mapping

vaccines. A randomized controlled trial in Cata<br>19 - Sandomized Controlled trial in Chile. Jama 2015. In Chile. Jama 2015<br>1920–1521 (1991–1520–1520–1527). In Chile. Jama 2015 34. Cattarino, L., Rodriguez-Barraquer, Amaryna, Dammings, Drammings, I., A. M. Marspelli, A. M. Marspelli, I<br>global variation in dengue transmission intensity. Sci. Transl. Med. 12, 1–11 (2020).<br>35. Cattarino Dengue vacci

35. WHO. Dengue vaccine: WHO position paper, September 2018 – Recommendations. Vaccine 37, 1988. Ned. 12019). 35. WHO. Dengar vacant vaccine; paper, September 2018 – Recommendations. Vacant 37,<br>4848–4849 (2019).  $\frac{4848}{1000}$ 

36. Rodríguez-Barraquer, I., Salje, H. & Cummings, D. A. Dengue pre-vaccination screening and<br>positive predictive values. Lancet Infect. Dis. 19, 132–134 (2019).<br>37. Thommes, E. et al. Public health impact an

vaccination screening' strategy with the dengue vaccine in Puerto Rico. Vaccine 40, 7343–7351 (2022). 38. St. John, A. L. & Rathore, A. P. S. Adaptive immune responses to primary and secondary dengue<br>virus infections. Nat. Rev. Immunol. 19. 218–230 (2019).

33. St. Johnson, A. L. Adaptive immune responses to primary and secondary analysis.<br>Virus infections. Nat. Rev. Immunol. 19, 218–230 (2019).<br>39. Kallás. F. G. et al. Live. attenuated. tetravalent Butantan–dengue v virus infections. Inferiormalistic infections.<br>19. Natalas, E. G. et al. Live, attenuated, tetravalent Bi<br>N. Fngl. J. Med. 390. 397–408 (2024). 39. Kallás, E. G. et al. Live, attenuated, tetravalent Butantan–dengue vaccine in children and adults.<br>N. Engl. J. Med. 390, 397–408 (2024).<br>40. Utarini, A. et al. Efficacy of wolbachia-infected mosquito de

N. Engl. J. Med. 384, 2177-2186 (2021). 440. Utamin, A. et al. Encourse, C. A. et al. A. et al. A. et al. et<br>N. Engl. J. Med. 384, 2177–2186 (2021).<br>41. Goethals. O. et al. Blocking NS3–NS4B interaction inhibits d

n. Engl. H. Med. 2177–2177–2121, 2021).<br>41. Goethals, O. et al. Blocking NS3-<br>Nature 615. 678–686 (2023).

Nature 615, 678–686 (2023).<br>42. Carpp, L. N. et al. Microneutralization assay titer correlates analysis in two phase 3 trials of the Nature 615, 678–615, 615–615, 6<br>42. Carpp, L. N. et al. Mic<br>CYD-TDV tetravalent dengue v 142. Carpp, L. N. et al. Microneutralization assay titer contracts analysis in the phase 3 trials of the<br>CYD-TDV tetravalent dengue vaccine in Asia and Latin America. PLOS ONE 15, e0234236 (2020).<br>43. Calman, A. & Rubin, D

43. Gelman, A. & Rubin, D. B. Inference from Iterative Simulation Using Multiple Sequences. Stat. Sci. 6. T. 457–472 13. General, A. B. B. Inference from Iterative Simulation Using Multiple Sequences. Stat. Stat. Stat. Stat. Sci<br>7, 457–472 (1992).<br>44. United Nations. World Population Prospects. (2022).

 $44.$  United Nat 44. United Nations. World Population Prospects. (2022).





Average seroprevalence in 9-year-olds









Average seroprevalence in 9-year-olds



DENV1 — DENV2 — DENV3 — DENV4 — NV - - VI

 $\overline{5}$ l3 2  $\overline{4}$